Literature DB >> 35502385

Oncological outcomes of patients with salivary gland cancer treated with surgery and postoperative intensity-modulated radiotherapy: a retrospective cohort study.

Shoumei Zang1, Meiqin Chen2, Huijie Huang3, Xinli Zhu1, Xinke Li1, Danfang Yan1, Senxiang Yan1.   

Abstract

Background: Salivary gland cancer (SGC) is relatively rare and constitutes a variety of histological subtypes. Previously published studies of SGC patients suggest that postoperative radiation using conventional radiotherapy (RT) or 3-dimensional (3D) conformal radiotherapy may have led to suboptimal oncological outcomes.
Methods: We identified 60 patients with major SGC treated with surgery followed by postoperative intensity-modulated radiotherapy (IMRT). Data for overall survival (OS), progression-free survival (PFS), locoregional relapse-free survival (LRRFS), distant metastasis-free survival (DMFS), prognostic factors, and treatment-related toxicities were analyzed. Survival was analyzed using the Kaplan-Meier method and compared using the log-rank test.
Results: With a median follow-up of 55.5 months, based on Kaplan-Meier analyses, the OS and PFS rates for SGC patients at 3, 5, and 10 years were 90.7%, 85.1%, and 85.1% and 80.1%, 72.7%, and 63.1%, respectively. The LRRFS and DMFS rates at 3, 5, and 10 years were 87.4%, 82.1%, and 82.1% and 85.3%, 78.4%, and 66.1%, respectively. In multivariable analysis (MVA), the node stage (N stage) was an independent predictor of PFS [P=0.047; hazard ratio (HR) =0.089]. A positive margin was a significant prognostic factor for PFS (P=0.036; HR =4.086), LRRFS (P=0.026; HR =5.064), and DMFS (P=0.011; HR =6.367). Major nerve involvement was significantly correlated with PFS (P=0.034; HR =2.394) and DMFS (P=0.008; HR =2.115). The interval from surgery to radiotherapy predicted PFS (P=0.036; HR =3.934) and DMFS (P=0.012; HR =6.231). Adenoid cystic carcinoma (ACC) was the most common histology (n=21; 35%). For ACC, the 5-year OS, PFS, LRRFS, and DMFS were 100%, 67.7%, 76.2%, and 90.2%, respectively. The most common acute toxicities were mucositis and dermatitis, and xerostomia was the most common late adverse event. Lung metastasis was the most common pattern of distant failure. Conclusions: N stage, positive margin, major nerve involvement, and interval from surgery to radiotherapy were important factors associated with PFS, LRRFS, and DMFS. Postoperative IMRT leads to improved survival for SGC patients, with acceptable toxicities. 2022 Quantitative Imaging in Medicine and Surgery. All rights reserved.

Entities:  

Keywords:  Salivary gland cancer (SGC); intensity-modulated radiotherapy (IMRT); survival

Year:  2022        PMID: 35502385      PMCID: PMC9014160          DOI: 10.21037/qims-21-836

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  37 in total

1.  Carcinoma of the major salivary glands treated by surgery or surgery plus postoperative radiotherapy.

Authors:  C A North; D J Lee; S Piantadosi; M Zahurak; M E Johns
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-06       Impact factor: 7.038

2.  World Health Organization classification of tumours: pathology and genetics of head and neck tumours.

Authors:  Lester Thompson
Journal:  Ear Nose Throat J       Date:  2006-02       Impact factor: 1.697

Review 3.  Apparent diffusion coefficient measurement of the parotid gland parenchyma.

Authors:  Maja Bruvo; Faisal Mahmood
Journal:  Quant Imaging Med Surg       Date:  2021-08

4.  Carcinoma of the parotid and submandibular glands--a study of survival in 2465 patients.

Authors:  Peter Wahlberg; H Anderson; A Biörklund; T Möller; R Perfekt
Journal:  Oral Oncol       Date:  2002-10       Impact factor: 5.337

5.  Cervical Lymph Node Metastatic Status and Adjuvant Therapy Predict the Prognosis of Salivary Duct Carcinoma.

Authors:  Kai Qian; Lu Di; Kai Guo; Xiaoke Zheng; Qinghai Ji; Zhuoying Wang
Journal:  J Oral Maxillofac Surg       Date:  2018-02-19       Impact factor: 1.895

6.  Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group.

Authors:  Chris H J Terhaard; H Lubsen; I Van der Tweel; F J M Hilgers; W M H Eijkenboom; H A M Marres; R E Tjho-Heslinga; J M A de Jong; J L N Roodenburg
Journal:  Head Neck       Date:  2004-08       Impact factor: 3.147

7.  Radiotherapy for parotid cancer.

Authors:  L M Toonkel; S Guha; P Foster; V Dembrow
Journal:  Ann Surg Oncol       Date:  1994-11       Impact factor: 5.344

8.  Salivary gland carcinoma in Denmark: a national update and follow-up on incidence, histology, and outcome.

Authors:  Marie Westergaard-Nielsen; Christian Godballe; Jesper Grau Eriksen; Stine Rosenkilde Larsen; Katalin Kiss; Tina Agander; Benedicte Parm Ulhøi; Birgitte Charabi; Tejs Ehlers Klug; Henrik Jacobsen; Jørgen Johansen; Claus Andrup Kristensen; Elo Andersen; Maria Andersen; Simon Andreasen; Kristine Bjørndal
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-07-20       Impact factor: 2.503

9.  Incidence and survival rates for malignant salivary gland tumors.

Authors:  Javier Ata-Ali; Oscar Zurriaga; Carmen Alberich
Journal:  J Oral Sci       Date:  2016       Impact factor: 1.556

10.  Salivary duct carcinoma.

Authors:  A Sefik Hosal; Chunyang Fan; Leon Barnes; Eugene N Myers
Journal:  Otolaryngol Head Neck Surg       Date:  2003-12       Impact factor: 5.591

View more
  1 in total

1.  Nomogram-Based Prediction of Overall and Disease-Specific Survival in Patients With Postoperative Major Salivary Gland Squamous Cell Carcinoma.

Authors:  Lixi Li; Di Zhang; Fei Ma
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.